David Jon Moliterno MD
Interventional Cardiology
Professor of Internal Medicine
Join to View Full Profile
900 S. Limestone, 326A CTWLexington, KY 40536
Phone+1 859-218-0121
Fax+1 859-257-6060
Dr. Moliterno is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Cardiovascular Disease, 1993 - 1994
University of Texas Southwestern Medical CenterFellowship, Cardiovascular Disease, 1990 - 1993
Vanderbilt University Medical CenterResidency, Internal Medicine, 1987 - 1990
Virginia Commonwealth University School of MedicineClass of 1987
Certifications & Licensure
KY State Medical License 2004 - 2026
OH State Medical License 1993 - 2012
TN State Medical License 1988 - 1994
TX State Medical License 1991 - 1994
American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Publications & Presentations
PubMed
- Characterizing high-risk enrollment criteria and impact on clinical outcomes in a large randomized clinical trial: Insights from the TWILIGHT trial.Philippe Gabriel Steg, Johny Nicolas, Usman Baber, Samantha Sartori, Zhongjie Zhang
American Heart Journal. 2025-08-01 - 1 citationsACS Management Guidelines: Tradition, Innovation, and the Gaps in Between.Mohamad Alkhouli, David J Moliterno
Journal of the American College of Cardiology. 2025-06-10 - Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT...Usman Baber, Davide Cao, Timothy Collier, Samantha Sartori, George Dangas
European Heart Journal. Cardiovascular Pharmacotherapy. 2025-02-08
Journal Articles
- CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary InterventionsDavid J Moliterno, Susan S Smyth, Ahmed Abdel-Latif, JAMA
- Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER TrialPaolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
Authored Content
- CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary InterventionsAugust 2020
Press Mentions
Short DAPT Safe in ACS with No Ischemic Penalty: 4D-ACSMay 30th, 2025- Meta-Analysis Quashes Hopes for Routine Embolic Protection in TAVIMay 21st, 2025
- Antithrombotic Therapy in High Bleeding Risk Part I: Percutaneous Cardiac InterventionsOctober 14th, 2024
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
